ClinicalTrials.gg
Active, not recruitingNCT06598462Updated Mar 20, 2026

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

A Phase 2 interventional study of Solrikitug Low Dose and Solrikitug Mid Dose in Eosinophilic Esophagitis (EoE), sponsored by Uniquity One (UNI). Active, not recruiting at 73 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Uniquity One (UNI) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 165 studies in Eosinophilic Esophagitis with a site in United States — 23 open to participants now, 41 under way, 3 of them phase 3. Eosinophilic Esophagitis · United States.

Enrollment
13th of 111
184 · median 36
Started
2024
with 5 others
Phase 2
30 of 165
3 open now
Primary completion
2027-04
later than 23 of 40 live
Registered
151st of 165
by date

Among the 165 studies in Eosinophilic Esophagitis with a site in United States, this one is the 13th largest by enrollment of the 111 interventional ones that give a count, is one of 6 that started in 2024, is one of 30 in phase 2, reaches primary completion later than 23 of the 40 other live ones, and was the 151st registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

23 of the 165 studies in Eosinophilic Esophagitis with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Eosinophilic Esophagitis with a site in United States, or all of them as a file.
02

Study summary

Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.

Read the detailed description

This is a 24-week randomized, double-blind, placebo-controlled Phase 2 clinical study with a 28-week extension to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of 3 dose levels of solrikitug versus placebo on top of standard of care in adult participants with EoE.

Approximately 180 adult participants with EoE will be randomized at approximately 80 sites. Participants will receive solrikitug, or placebo, administered via subcutaneous injection at the study site, over a 24-week treatment period followed by a 28-week extension period. The study also includes a post-treatment follow-up period of 16 weeks.

03

Conditions studied

  • Eosinophilic Esophagitis (EoE)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria

Part A

  • Participant must be 18 to 75 years of age inclusive, at the time of signing the .
  • Established diagnosis of EoE with a previous EGD and esophageal confirming diagnosis of EoE.
  • Participants who have symptomatic EoE as defined by a history of on average at least 2 episodes of dysphagia per week in the 4 weeks prior to Screening.
  • Must remain on a stabilized diet for at least 8 weeks prior to Visit 1 and during the course of the study.
  • May be on any background PPI and/or STC, during the course of the study, as long as background medications have been stable for at least 8 weeks prior to the Screening and must agree to no changes to background medication or dosage unless medically indicated.
  • Discontinuation of any marketed drug or biologic (monoclonal or polyclonal antibody) within 30 days or 5 half-lives prior to screening, whichever is longer.
  • Participants should have previously documented standard of care treatment, which could include PPI and/or STC and/or diet.

Key exclusion criteria

Part A

  • Female participant who is pregnant or breastfeeding.
  • Have a history or presence of any other gastrointestinal disorders such as active Helicobacter pylori infection, history of achalasia, hyper eosinophilic syndrome and eosinophilic granulomatosis with polyangiitis, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory bowel disease, celiac disease, eosinophilic enteritis, gastritis, colitis, diverticulitis, irritable bowel syndrome, or other gastrointestinal conditions as per Investigator discretion.
  • Esophageal stricture that prevents the easy passage of a standard endoscope or any critical esophageal stricture that requires dilation at screening.
  • Esophageal dilation performed within 8 weeks prior to screening.
  • Participant has a known to any component of the formulation of solrikitug, including any of the , or a history of anaphylactic reaction to any therapeutic monoclonal antibody.

Part B

  • Participants who, during Part A, developed a serious adverse event (SAE) and/or adverse event (AE) deemed related to study drug, which in the opinion of the investigator could indicate that continued treatment with study drug may present and unreasonable risk to the participant.
  • Participants who became pregnant during Part A.
  • Participants who are prematurely discontinued from study drug due to AE (patients who are prematurely discontinued from study drug due to lack of efficacy are eligible to enter Part B).
  • Patients who did not undergo endoscopy with biopsies prior to receiving rescue treatment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    Solrikitug low dose

    Solrikitug

    Biological: Solrikitug Low Dose

  • Experimental
    Solrikitug mid dose

    Solrikitug

    Biological: Solrikitug Mid Dose

  • Experimental
    Solrikitug high dose

    Solrikitug

    Biological: Solrikitug High Dose

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • BiologicalSolrikitug Low Dose

    Solrikitug low dose subcutaneous injection

  • BiologicalSolrikitug Mid Dose

    Solrikitug mid dose subcutaneous injection

  • BiologicalSolrikitug High Dose

    Solrikitug high dose subcutaneous injection

  • OtherPlacebo

    Placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Histological response of peak esophageal eosinophil per HPF count of ≤6

    Time frame: Week 24

  2. Change from baseline in DSQ (Dysphagia Symptom Questionnaire) score

    The DSQ score is calculated over 14-day period and ranges from 0 to 84, with a lower score indicating less severe dysphagia.

    Time frame: Week 24

Secondary outcomes

  1. Adverse events (AEs) and serious adverse events (SAEs)

    Time frame: To Week 24

07

Study locations

73 sites
  • Research Site 1039
    Dothan, Alabama 36305, United States
  • Research Site 1018
    Glendale, Arizona 85306, United States
  • Research Site 1018
    Peoria, Arizona 85306, United States
  • Research Site 1037
    Scottsdale, Arizona 85258, United States
  • Research Site 1003
    Tucson, Arizona 85715, United States
  • Research Site 1023
    Englewood, California 90301, United States
  • Research Site 1005
    Irvine, California 92618, United States
  • Research Site 1015
    San Diego, California 92120, United States
  • Research Site 1034
    Aurora, Colorado 80045, United States
  • Research Site 1027
    Cromwell, Connecticut 06416, United States
  • Research Site 1040
    Inverness, Florida 34452, United States
  • Research Site 1001
    Jacksonville, Florida 32256, United States
  • Research Site 1049
    Miami, Florida 33155, United States
  • Research Site 1007
    Boise, Idaho 83706, United States
  • Research Site 1048
    Glenview, Illinois 60026, United States
  • Research Site 1022
    Iowa City, Iowa 52242, United States
  • Research Site 1033
    Topeka, Kansas 66606, United States
  • Research Site 1032
    Chevy Chase, Maryland 20815, United States
  • Research Site 1004
    Boston, Massachusetts 02111, United States
  • Research Site 1024
    Ann Arbor, Michigan 48109, United States
  • Research Site 1013
    Wyoming, Michigan 49519, United States
  • Research Site 1006
    Plymouth, Minnesota 55446, United States
  • Research Site 1042
    Creve Coeur, Missouri 63141, United States
  • Research Site 1016
    Reno, Nevada 89511, United States
  • Research Site 1045
    Freehold, New Jersey 07728, United States
  • Research Site 1043
    Jackson, New Jersey 08527, United States
  • Research Site 1026
    Chapel Hill, North Carolina 27599, United States
  • Research Site 1021
    High Point, North Carolina 27265, United States
  • Research Site 1012
    Columbus, Ohio 43213, United States
  • Research Site 1020
    Harrisburg, Pennsylvania 17110, United States
  • Research Site 1030
    Philadelphia, Pennsylvania 19104, United States
  • Research Site 1014
    Dallas, Texas 75230, United States
  • Research Site 1008
    Houston, Texas 77494, United States
  • Research Site 1036
    Pearland, Texas 77584, United States
  • Research Site 1041
    Rockwell, Texas 75032, United States
  • Research Site 1002
    Ogden, Utah 84405, United States
  • Research Site 1019
    Salt Lake City, Utah 84132, United States
  • Research Site 1017
    Sandy City, Utah 84092, United States
  • Research Site 1108
    Newcastle, New South Wales 02111, Australia
  • Research Site 1110
    Maroochydore, Queensland 4558, Australia
  • Research Site 1103
    South Brisbane, Queensland 4101, Australia
  • Research Site 1107
    Woolloongabba, Queensland 4102, Australia
  • Research Site 1106
    Box Hill, Victoria 3128, Australia
  • Research Site 1102
    Fitzroy, Victoria 3065, Australia
  • Research Site 1101
    Parkville, Victoria 3010, Australia
  • Research Site 1109
    Murdoch, Western AUS 6050, Australia
  • Research Site 1111
    Maroochydore, QLD 4558, Australia
  • Research Site 1107
    Woolloongabba, QLD 4102, Australia
  • Research Site 1151
    Leuven, VLG 3000, Belgium
  • Research Site 1152
    Bruges, 8310, Belgium
  • Research Site 1153
    Tournai, 7500, Belgium
  • Research Site 1252
    Milan, Ca'Granada 20122, Italy
  • Research Site 1256
    Campobasso, IT 86100, Italy
  • Research Site 1253
    Padova, IT 35128, Italy
  • Research Site 1255
    Roma, IT 00168, Italy
  • Research Site 1259
    Pieve Emanuele, MI 20072, Italy
  • Research Site 1258
    Verona, 37134, Italy
  • Research Site 1303
    Maastricht, AZ 6202, Netherlands
  • Research Site 1302
    Rotterdam, 3000, Netherlands
  • Research Site 1207
    Lodz, 90-752, Poland
  • Research Site 1202
    Szczecin, 04-501, Poland
  • Research Site 1205
    Tychy, 43-100, Poland
  • Research Site 1203
    Warsaw, 00-189, Poland
  • Research Site 1206
    Warsaw, 02-781, Poland
  • Research Site 1204
    Warsaw, 04-141, Poland
  • Research Site 1201
    Warsaw, 04-501, Poland
  • Research Site 1354
    Barcelona, 08022, Spain
  • Research Site 1353
    Madrid, 28006, Spain
  • Research Site 1352
    Madrid, 28040, Spain
  • Research Site 1351
    Tomelloso, 13700, Spain
  • Research Site 1402
    Zurich, 8044, Switzerland
  • Research Site 1551
    Whitechapel, London E1 1BB, United Kingdom
  • Research Site 1553
    London, Tooting SW17 0GT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 30 months after the start.

Of 24 phase 2 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's planned 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2024
First posted
Sep 19, 2024
StartActual
Oct 16, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
Aug 31, 2027
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06598462
Lead sponsor
Uniquity One (UNI)
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 16, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Mar 20, 2026

Study contacts

Andrew W Lee, MD
study chair · Vice President, Clinical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion